Correlation between serial measurements of N‐terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure

Serial measurements of N‐terminal pro brain natriuretic peptide (NT‐proBNP) have been suggested for the management of outpatients with chronic heart failure (CHF). The relationship between NT‐proBNP plasma levels and central haemodynamic parameters in this setting is not known.

[1]  A. Maisel,et al.  B-type natriuretic peptide in the diagnosis and management of congestive heart failure. , 2001, Cardiology clinics.

[2]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[3]  M. Redfield,et al.  The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. , 2002, Journal of cardiac failure.

[4]  L. Rydén,et al.  Continuous ambulatory haemodynamic monitoring with an implantable system. The feasibility of a new technique. , 1998, European heart journal.

[5]  L. Lenert,et al.  Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. , 2001, Journal of the American College of Cardiology.

[6]  R C Littell,et al.  Mixed Models: Modelling Covariance Structure in the Analysis of Repeated Measures Data , 2005 .

[7]  F. Braunschweig,et al.  Continuous Hemodynamic Monitoring in Heart Failure , 2002, Journal of cardiovascular electrophysiology.

[8]  L. Rydén,et al.  Monitoring of pulmonary arterial diastolic pressure through a right ventricular pressure transducer. , 1995, Journal of cardiac failure.

[9]  M. Pfeffer,et al.  Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. , 2002, Journal of the American College of Cardiology.

[10]  H. Hense,et al.  Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. , 1998, Journal of the American College of Cardiology.

[11]  D. Murdoch,et al.  Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. , 1999, American heart journal.

[12]  M. Kinoshita,et al.  Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. , 1998, American heart journal.

[13]  N. Freemantle,et al.  Clinical trials update from the American College of Cardiology meeting: CARE‐HF and the Remission of Heart Failure, Women's Health Study, TNT, COMPASS‐HF, VERITAS, CANPAP, PEECH and PREMIER , 2005, European journal of heart failure.

[14]  M. Quiñones,et al.  Optimal Noninvasive Assessment of Left Ventricular Filling Pressures: A Comparison of Tissue Doppler Echocardiography and B-Type Natriuretic Peptide in Patients With Pulmonary Artery Catheters , 2004, Circulation.

[15]  L. Stevenson,et al.  The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. , 1989, JAMA.

[16]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[17]  E. Shapiro,et al.  Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit , 2005 .

[18]  L. Rydén,et al.  Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. , 2003, Journal of the American College of Cardiology.

[19]  L. Lenert,et al.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.

[20]  R. T. Lie,et al.  Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. , 1996, Circulation.

[21]  M. Kinoshita,et al.  Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[22]  J. Burnett,et al.  BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. , 1997, The American journal of physiology.

[23]  P. Krishnaswamy,et al.  Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide. , 2002, American heart journal.

[24]  Philip Adamson,et al.  Continuous ambulatory right heart pressure measurements with an implantable hemodynamic monitor: a multicenter, 12-month follow-up study of patients with chronic heart failure. , 2002, Journal of cardiac failure.

[25]  F. Marumo,et al.  Plasma human brain natriuretic peptide in chronic renal failure. , 1995, Clinical nephrology.

[26]  R. Wilson,et al.  Measurement of pulmonary artery diastolic pressure from a right ventricular pressure transducer in patients with heart failure. , 1996, Journal of cardiac failure.

[27]  O. Vuolteenaho,et al.  Involvement of transcriptional and posttranscriptional mechanisms in cardiac overload-induced increase of B-type natriuretic peptide gene expression. , 1997, Circulation research.

[28]  J. Potter,et al.  Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 2005, The American journal of cardiology.

[29]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[30]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[31]  P. Ivarsen,et al.  A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. , 1997, Scandinavian journal of clinical and laboratory investigation.